Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1641) 1641
Book Review (342) 342
Publication (165) 165
Book / eBook (4) 4
Dissertation (2) 2
Book Chapter (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1604) 1604
index medicus (1571) 1571
male (1030) 1030
female (1028) 1028
hematology (882) 882
child (830) 830
adolescent (800) 800
oncology (799) 799
child, preschool (645) 645
precursor cell lymphoblastic leukemia-lymphoma - mortality (622) 622
adult (573) 573
prognosis (538) 538
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (524) 524
cancer (496) 496
infant (479) 479
leukemia (444) 444
children (443) 443
precursor cell lymphoblastic leukemia-lymphoma - therapy (443) 443
acute lymphocytic leukemia (438) 438
treatment outcome (432) 432
middle aged (425) 425
chemotherapy (400) 400
acute lymphoblastic leukemia (397) 397
precursor cell lymphoblastic leukemia-lymphoma - genetics (392) 392
precursor cell lymphoblastic leukemia-lymphoma - pathology (336) 336
antineoplastic combined chemotherapy protocols - therapeutic use (333) 333
disease-free survival (305) 305
pediatrics (282) 282
acute lymphoblastic-leukemia (276) 276
young adult (274) 274
transplantation (271) 271
minimal residual disease (269) 269
survival rate (269) 269
aged (264) 264
risk factors (261) 261
recurrence (259) 259
remission induction (253) 253
care and treatment (243) 243
therapy (240) 240
survival analysis (232) 232
research (227) 227
retrospective studies (226) 226
childhood (214) 214
precursor cell lymphoblastic leukemia-lymphoma - diagnosis (204) 204
health aspects (198) 198
precursor b-cell lymphoblastic leukemia-lymphoma - mortality (180) 180
acute lymphocytic-leukemia (174) 174
acute myeloid-leukemia (173) 173
acute lymphatic leukemia (170) 170
analysis (169) 169
stem-cell transplantation (169) 169
survival (166) 166
bone-marrow-transplantation (165) 165
abridged index medicus (162) 162
relapse (160) 160
animals (158) 158
stem cells (157) 157
risk (156) 156
genetic aspects (155) 155
hematopoietic stem cell transplantation (153) 153
follow-up studies (151) 151
hematology, oncology and palliative medicine (149) 149
antineoplastic agents - therapeutic use (146) 146
transplantation, homologous (146) 146
immunology (139) 139
hematopoietic stem cells (131) 131
article (128) 128
t cells (126) 126
philadelphia chromosome (125) 125
precursor b-cell lymphoblastic leukemia-lymphoma - genetics (123) 123
bone marrow (122) 122
medicine & public health (121) 121
expression (120) 120
precursor cell lymphoblastic leukemia-lymphoma - complications (118) 118
immunophenotyping (117) 117
adults (116) 116
diagnosis (116) 116
lymphatic leukemia (112) 112
mice (110) 110
precursor cell lymphoblastic leukemia-lymphoma - immunology (110) 110
age factors (107) 107
all (106) 106
combined modality therapy (103) 103
patients (103) 103
kaplan-meier estimate (101) 101
mortality (101) 101
precursor b-cell lymphoblastic leukemia-lymphoma - drug therapy (101) 101
antineoplastic combined chemotherapy protocols - adverse effects (100) 100
gene expression (97) 97
precursor cell lymphoblastic leukemia-lymphoma - epidemiology (97) 97
precursor cell lymphoblastic leukemia-lymphoma - metabolism (97) 97
infant, newborn (91) 91
patient outcomes (91) 91
hemic and lymphatic diseases (90) 90
remission (90) 90
neoplasm, residual (88) 88
adolescents (87) 87
precursor b-cell lymphoblastic leukemia-lymphoma - pathology (86) 86
hematopoietic stem cell transplantation - methods (84) 84
stem cell transplantation (82) 82
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1611) 1611
Chinese (12) 12
Japanese (7) 7
German (3) 3
French (2) 2
Norwegian (2) 2
Russian (2) 2
Spanish (2) 2
Danish (1) 1
Italian (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
by Topp, Max S and Gökbuget, Nicola and Zugmaier, Gerhard and Klappers, Petra and Stelljes, Matthias and Neumann, Svenja and Viardot, Andreas and Marks, Reinhard and Diedrich, Helmut and Faul, Christoph and Reichle, Albrecht and Horst, Heinz-August and Brüggemann, Monika and Wessiepe, Dorothea and Holland, Chris and Alekar, Shilpa and Mergen, Noemi and Einsele, Hermann and Hoelzer, Dieter and Bargou, Ralf C
Journal of Clinical Oncology, ISSN 0732-183X, 12/2014, Volume 32, Issue 36, pp. 4134 - 4140
Purpose Patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have a dismal prognosis. CD19 is homogenously expressed in B-precursor ALL and... 
SALVAGE | ONCOLOGY | PROGNOSIS | INOTUZUMAB OZOGAMICIN | ACUTE LYMPHOCYTIC-LEUKEMIA | ADULTS | ANTIBODY | FAILURE | CHEMOTHERAPY | MRD | Recurrence | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Remission Induction | Neoplasm, Residual | Antibodies, Bispecific - therapeutic use | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Bispecific - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adolescent | Adult | Female | Aged | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
by Gökbuget, Nicola and Dombret, Hervé and Bonifacio, Massimiliano and Reichle, Albrecht and Graux, Carlos and Faul, Christoph and Diedrich, Helmut and Topp, Max S and Brüggemann, Monika and Horst, Heinz-August and Havelange, Violaine and Stieglmaier, Julia and Wessels, Hendrik and Haddad, Vincent and Benjamin, Jonathan E and Zugmaier, Gerhard and Nagorsen, Dirk and Bargou, Ralf C
Blood, ISSN 0006-4971, 04/2018, Volume 131, Issue 14, pp. 1522 - 1531
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission aftermultiagent therapy exhibit minimal residual... 
ALLOGENEIC TRANSPLANTATION | REDUCED-INTENSITY | RELAPSE | COMPLETE REMISSION | STANDARD-RISK | FREE SURVIVAL | ENGAGING ANTIBODY | HEMATOLOGY | MRD | CHEMOTHERAPY | CLINICAL-SIGNIFICANCE | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Humans | Middle Aged | Male | Survival Rate | Neoplasm, Residual | Disease-Free Survival | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Bispecific - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Bispecific - administration & dosage | Adolescent | Adult | Female | Aged | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
by Kantarjian, Hagop and Stein, Anthony and Gökbuget, Nicola and Fielding, Adele K and Schuh, Andre C and Ribera, Josep-Maria and Wei, Andrew and Dombret, Hervé and Foà, Robin and Bassan, Renato and Arslan, Önder and Sanz, Miguel A and Bergeron, Julie and Demirkan, Fatih and Lech-Maranda, Ewa and Rambaldi, Alessandro and Thomas, Xavier and Horst, Heinz-August and Brüggemann, Monika and Klapper, Wolfram and Wood, Brent L and Fleishman, Alex and Nagorsen, Dirk and Holland, Christopher and Zimmerman, Zachary and Topp, Max S
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 9, pp. 836 - 847
Among adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, treatment with the bispecific anti-CD19 and anti-CD3 monoclonal... 
ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | HYPER-CVAD | INOTUZUMAB OZOGAMICIN | ACUTE LYMPHOCYTIC-LEUKEMIA | SALVAGE THERAPY | MONOCLONAL-ANTIBODY | PROGNOSTIC-SIGNIFICANCE | STEM-CELL TRANSPLANTATION | T-CELLS | CHAIN ANTIBODY CONSTRUCT | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Transplantation, Homologous | Stem Cell Transplantation | Young Adult | Antibodies, Bispecific - therapeutic use | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Bispecific - adverse effects | Sepsis - chemically induced | Antineoplastic Agents - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Chemotherapy | Usage | Care and treatment | Acute lymphocytic leukemia | Diagnosis | Comparative analysis | Patients | Cancer | CD19 antigen | Acute lymphatic leukemia | Cell survival | Writers | Clinical trials | Stem cell transplantation | Lymphocytes T | CD3 antigen | Lymphatic leukemia | Lymphocytes B | Medical prognosis | Monoclonal antibodies | Remission | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
by Roberts, Kathryn G and Li, Yongjin and Payne-Turner, Debbie and Harvey, Richard C and Yang, Yung-Li and Pei, Deqing and McCastlain, Kelly and Ding, Li and Lu, Charles and Song, Guangchun and Ma, Jing and Becksfort, Jared and Rusch, Michael and Chen, I-Ming and Chen, Xiang and Chen, Shann-Ching and Easton, John and Cheng, Jinjun and Cheng, Cheng and Boggs, Kristy and Santiago-Morales, Natalia and Iacobucci, Ilaria and Fulton, Robert S and Wen, Ji and Valentine, Marcus and Paugh, Steven W and Devidas, Meenakshi and Reshmi, Shalini and Smith, Malcolm A and Smith, Amy and Hedlund, Erin and Gupta, Pankaj and Nagahawatte, Panduka and Wu, Gang and Yergeau, Donald and Vadodaria, Bhavin and Mulder, Heather and Winick, Naomi J and Larsen, Eric C and Carroll, Andrew J and Carroll, William L and Heerema, Nyla A and Grayson, Guy and Tasian, Sarah K and Moore, Andrew S and Keller, Frank and Frei-Jones, Melissa and Whitlock, James A and Raetz, Elizabeth A and White, Deborah L and Hughes, Timothy P and Guidry Auvil, Jaime M and Marcucci, Guido and Bloomfield, Clara D and Mrózek, Krzysztof and Kohlschmidt, Jessica and Stock, Wendy and Kornblau, Steven M and Konopleva, Marina and Paietta, Elisabeth and Pui, Ching-Hon and Jeha, Sima and Relling, Mary V and Evans, William E and Gerhard, Daniela S and Gastier-Foster, Julie M and Mardis, Elaine and Wilson, Richard K and Loh, Mignon L and Downing, James R and Hunger, Stephen P and Willman, Cheryl L and Zhang, Jinghui and Mullighan, Charles G
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 1005 - 1015
About 25% of young adults with ALL have Ph-like genotypes, which are associated with poor outcomes with conventional treatment. In this gene-expression study,... 
MEDICINE, GENERAL & INTERNAL | MODELS | B-CELL PRECURSOR | INHIBITOR THERAPY | IMATINIB | PEDIATRIC ACUTE LEUKEMIAS | GENE FUSION | EXPRESSION | ETV6-NTRK3 FUSION TRANSCRIPTS | CRLF2 | DELETION | Oligonucleotide Array Sequence Analysis | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Humans | Child, Preschool | Infant | Male | Young Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Heterografts | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adult | Female | DNA, Neoplasm - analysis | Receptors, Cytokine - metabolism | Child | Philadelphia Chromosome | Receptors, Cytokine - genetics | Signal Transduction - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Adolescent | Survival Analysis | Mice | Polymorphism, Single Nucleotide | Genome, Human | Protein-Tyrosine Kinases - antagonists & inhibitors | Development and progression | Care and treatment | Genetic aspects | Research | Lymphocytic leukemia | Tyrosine metabolism | Cell proliferation | Adolescence | Tyk2 protein | Leukemia | Genes | Clinical trials | Oncology | Genomes | Kinases | Cell activation | Janus kinase 2 | Xenografts | Teenagers | Children | Protein-tyrosine kinase | Age | Tyrosine | Young adults | Genomic analysis | Acute lymphatic leukemia | Stat5 protein | Lymphatic leukemia | Gene expression | Philadelphia chromosome | Interleukin 7 receptors | Thymic stromal lymphopoietin | Lymphocytes B | Cell lines | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
by Topp, Max S, Dr and Gökbuget, Nicola, MD and Stein, Anthony S, MD and Zugmaier, Gerhard, MD and O'Brien, Susan, MD and Bargou, Ralf C, Prof and Dombret, Hervé, MD and Fielding, Adele K, PhD and Heffner, Leonard, MD and Larson, Richard A, Prof and Neumann, Svenja, MD and Foà, Robin, MD and Litzow, Mark, Prof and Ribera, Josep-Maria, Prof and Rambaldi, Alessandro, MD and Schiller, Gary, MD and Brüggemann, Monika, MD and Horst, Heinz A, MD and Holland, Chris, MS and Jia, Catherine, PhD and Maniar, Tapan, MD and Huber, Birgit, PhD and Nagorsen, Dirk, MD and Forman, Stephen J, MD and Kantarjian, Hagop M, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 57 - 66
Summary Background Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific... 
Hematology, Oncology and Palliative Medicine | CELL-ENGAGING ANTIBODY | SALVAGE | SURVIVAL | TRIALS | THERAPY | ONCOLOGY | INOTUZUMAB OZOGAMICIN | ACUTE LYMPHOCYTIC-LEUKEMIA | T-CELLS | CHEMOTHERAPY | CHAIN ANTIBODY CONSTRUCT | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Age Factors | United States | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Bispecific - administration & dosage | Adult | Female | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Remission Induction | Antibodies, Bispecific - therapeutic use | Disease-Free Survival | Antibodies, Bispecific - adverse effects | Adolescent | Intention to Treat Analysis | Aged | Infusions, Intravenous | T cells | Adults | Safety and security measures | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: A report from children's oncology group study AALL0232
by Larsen, Eric C and Devidas, Meenakshi and Chen, Si and Salzer, Wanda L and Raetz, Elizabeth A and Loh, Mignon L and Mattano, Leonard A and Cole, Catherine and Eicher, Alisa and Haugan, Maureen and Sorenson, Mark and Heerema, Nyla A and Carroll, Andrew A and Gastier-Foster, Julie M and Borowitz, Michael J and Wood, Brent L and Willman, Cheryl L and Winick, Naomi J and Hunger, Stephen P and Carroll, William L
Journal of Clinical Oncology, ISSN 0732-183X, 07/2016, Volume 34, Issue 20, pp. 2380 - 2388
Purpose Survival for children and young adults with high-risk B-acute lymphoblastic leukemia has improved significantly, but 20% to 25% of patients are not... 
ASPARAGINASE | PHARMACOKINETICS | ONCOLOGY | ADOLESCENTS | CONSECUTIVE TRIALS | BFM STUDY-GROUP | CANCER GROUP | CORTICOSTEROIDS | MINIMAL RESIDUAL DISEASE | CHILDHOOD | PREDNISOLONE | Dexamethasone - administration & dosage | Humans | Child, Preschool | Dexamethasone - adverse effects | Infant | Male | Young Adult | Methotrexate - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adult | Female | Methotrexate - administration & dosage | Child | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
by Topp, Max S and Gökbuget, Nicola and Zugmaier, Gerhard and Degenhard, Evelyn and Goebeler, Marie-Elisabeth and Klinger, Matthias and Neumann, Svenja A and Horst, Heinz A and Raff, Thorsten and Viardot, Andreas and Stelljes, Matthias and Schaich, Markus and Köhne-Volland, Rudolf and Brüggemann, Monika and Ottmann, Oliver G and Burmeister, Thomas and Baeuerle, Patrick A and Nagorsen, Dirk and Schmidt, Margit and Einsele, Hermann and Riethmüller, Gert and Kneba, Michael and Hoelzer, Dieter and Kufer, Peter and Bargou, Ralf C
Blood, ISSN 0006-4971, 12/2012, Volume 120, Issue 26, pp. 5185 - 5187
Persistence or recurrence of minimal residual disease (MRD) after chemotherapy results in clinical relapse in patients with acute lymphoblastic leukemia (ALL).... 
CELL-ENGAGING ANTIBODY | ADULT PATIENTS | TRIALS | THERAPY | PROGNOSTIC-FACTORS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Follow-Up Studies | Humans | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Antineoplastic Agents - therapeutic use | Combined Modality Therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Transplantation, Homologous | Neoplasm, Residual | Antibodies, Bispecific - therapeutic use | Disease-Free Survival | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Survival Analysis | Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - blood | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype
by Migliorini, Gabriele and Migliorini, Gabriele and Fiege, Bettina and Fiege, Bettina and Hosking, Fay J and Hosking, Fay J and Ma, Yussanne and Ma, Yussanne and Kumar, Rajiv and Kumar, Rajiv and Sherborne, Amy L and Sherborne, Amy L and da Silva Filho, Miguel Inacio and Da Silva Filho, Miguel Inacio and Vijayakrishnan, Jayaram and Vijayakrishnan, Jayaram and Koehler, Rolf and Koehler, Rolf and Thomsen, Hauke and Thomsen, Hauke and Irving, Julie A and Irving, Julie A and Allan, James M and Allan, James M and Lightfoot, Tracy and Lightfoot, Tracy and Roman, Eve and Roman, Eve and Kinsey, Sally E and Kinsey, Sally E and Sheridan, Eamonn and Sheridan, Eamonn and Thompson, Pamela and Thompson, Pamela and Hoffmann, Per and Hoffmann, Per and Nöthen, Markus M and Nöthen, Markus M and Mühleisen, Thomas W and Mühleisen, Thomas W and Eisele, Lewin and Eisele, Lewin and Zimmermann, Martin and Zimmermann, Martin and Bartram, Claus R and Bartram, Claus R and Schrappe, Martin and Schrappe, Martin and Greaves, Mel and Greaves, Mel and Stanulla, Martin and Stanulla, Martin and Hemminki, Kari and Hemminki, Kari and Houlston, Richard S and Houlston, Richard S and Allmänmedicin, psykiatrisk epidemiologi och migration and EpiHealth: Epidemiology for Health and Lund University and Family Medicine, Psychiatric Epidemiology and Migration and Lunds universitet
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 19, pp. 3298 - 3307
Acute lymphoblastic leukemia (ALL) is the major pediatric cancer diagnosed in economically developed countries with B-cell precursor (BCP)-ALL, accounting for... 
POPULATION | VARIANTS | SEQUENCE | SUSCEPTIBILITY LOCI | PIP5K2A | SCHIZOPHRENIA | GATA3 | HUMAN BREAST-TUMORS | HEMATOLOGY | GENOME-WIDE ASSOCIATION | CHILDREN | GATA3 Transcription Factor - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Age Factors | Exons | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Genetic Loci | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Female | B-Lymphocytes - pathology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Child | B-Lymphocytes - metabolism | Genetic Predisposition to Disease | Genome-Wide Association Study | Introns | Phosphotransferases (Alcohol Group Acceptor) - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Phenotype | Alleles | Survival Analysis | Polymorphism, Single Nucleotide | Chromosomes, Human, Pair 10 | Index Medicus | Abridged Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children's Oncology Group study AALL0232
by Borowitz, Michael J and Wood, Brent L and Devidas, Meenakshi and Loh, Mignon L and Raetz, Elizabeth A and Salzer, Wanda L and Nachman, James B and Carroll, Andrew J and Heerema, Nyla A and Gastier-Foster, Julie M and Willman, Cheryl L and Dai, Yunfeng and Winick, Naomi J and Hunger, Stephen P and Carroll, William L and Larsen, Eric
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 8, pp. 964 - 971
Minimal residual disease (MRD) is highly prognostic in pediatric B-precursor acute lymphoblastic leukemia (B-ALL). In Children's Oncology Group high-risk B-ALL... 
RELAPSE | STANDARDIZATION | THERAPY | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | MOLECULAR RESPONSE | QUALITY-CONTROL | STEM-CELL TRANSPLANTATION | HEMATOLOGY | CHEMOTHERAPY | PCR | Neoplasm, Residual - pathology | Leucovorin - administration & dosage | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Prognosis | Humans | Child, Preschool | Induction Chemotherapy | Male | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Flow Cytometry | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Female | Maintenance Chemotherapy | Child | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Polyethylene Glycols - administration & dosage | Asparaginase - administration & dosage | Disease-Free Survival | Methotrexate - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
by Gokbuget, N and Dombret, H and Ribera, JM and Fielding, AK and Advani, A and Bassan, R and Chia, V and Doubek, M and Giebel, S and Hoelzer, D and Ifrah, N and Katz, A and Kelsh, M and Martinelli, G and Morgades, M and O'Brien, S and Rowe, JM and Stieglmaier, J and Wadleigh, M and Kantarjian, H
HAEMATOLOGICA, ISSN 0390-6078, 12/2016, Volume 101, Issue 12, pp. 1524 - 1533
Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To... 
TRIAL | RELAPSE | REMISSIONS | PROGNOSIS | ACUTE LYMPHOCYTIC-LEUKEMIA | SALVAGE THERAPY | PHASE-II | BLINATUMOMAB | HEMATOLOGY | Recurrence | Prognosis | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Treatment Outcome | Combined Modality Therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy | Remission Induction | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Young Adult | Retreatment | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Philadelphia Chromosome | Health Care Surveys | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia
by Jabbour, Elias and Short, Nicholas J and Jorgensen, Jeffrey L and Yilmaz, Musa and Ravandi, Farhad and Wang, Sa A and Thomas, Deborah A and Khoury, Joseph and Champlin, Richard E and Khouri, Issa and Kebriaei, Partow and O'Brien, Susan M and Garcia‐Manero, Guillermo and Cortes, Jorge E and Sasaki, Koji and Dinardo, Courtney D and Kadia, Tapan M and Jain, Nitin and Konopleva, Marina and Garris, Rebecca and Kantarjian, Hagop M
Cancer, ISSN 0008-543X, 01/2017, Volume 123, Issue 2, pp. 294 - 302
In adults with relapsed/refractory acute lymphoblastic leukemia who are receiving their first salvage therapy, the achievement of minimal residual disease... 
relapsed | refractory | inotuzumab | blinatumomab | minimal residual disease | acute lymphoblastic leukemia | ADULT PATIENTS | PROGNOSIS | INOTUZUMAB OZOGAMICIN | ACUTE LYMPHOCYTIC-LEUKEMIA | INDUCTION | TRANSPLANTATION | ONCOLOGY | FLOW-CYTOMETRY | MRD | CLINICAL-SIGNIFICANCE | Neoplasm, Residual - pathology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Humans | Middle Aged | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Young Adult | Disease-Free Survival | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Stem Cell Transplantation - methods | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adolescent | Aged, 80 and over | Adult | Aged | B-Lymphocytes - pathology | Hematopoietic Stem Cell Transplantation - methods | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Salvage Therapy - methods | Flow cytometry | Cell survival | Acute lymphatic leukemia | Identification methods | Leukemia | Minimal residual disease | Stem cell transplantation | Transplantation | Lymphatic leukemia | Patients | Survival | Doxorubicin | Vincristine | Cytometry | Cyclophosphamide | Salvage | Lymphocytes B | Stem cells | Remission | Adults | Cancer | Index Medicus | Abridged Index Medicus | Acute lymphoblastic leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: Results of the EORTC Children's Leukemia Group study 58951
by Clappier, E and Grardel, N and Bakkus, M and Rapion, J and De Moerloose, B and Kastner, P and Caye, A and Vivent, J and Costa, V and Ferster, A and Lutz, P and Mazingue, F and Millot, F and Plantaz, D and Plat, G and Plouvier, E and Poirée, M and Sirvent, N and Uyttebroeck, A and Yakouben, K and Girard, S and Dastugue, N and Suciu, S and Benoit, Y and Bertrand, Y and Cavé, H and EORTC-CLG and European Organisation for Research and Treatment of Cancer, Children's Leukemia Group (EORTC-CLG) and on behalf of the EORTC-CLG
Leukemia, ISSN 0887-6924, 11/2015, Volume 29, Issue 11, pp. 2154 - 2161
The added value of IKZF1 gene deletion (IKZF1(del)) as a stratifying criterion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is still debated. We... 
RELAPSE | DEXAMETHASONE | ERG DELETION | ONCOLOGY | VINCRISTINE | RANDOMIZED-TRIAL | RISK | INDUCTION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | EXPRESSION | GENETIC ALTERATIONS | Recurrence | Prognosis | Humans | Child, Preschool | Infant | Male | Ikaros Transcription Factor - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Gene Deletion | Adolescent | Female | Child | Development and progression | Care and treatment | Acute lymphocytic leukemia | Research | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights